Quantum-Si to Present at the 2024 American Society of Human Genetics Annual Meeting
Quantum-Si (Nasdaq: QSI) announced its participation in the 2024 American Society of Human Genetics Annual Meeting, where it will present on Next-Generation Protein Sequencing (NGPS) technology. The presentation, titled 'From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein Sequencing Technology,' will feature Dr. Meredith Carpenter and Dr. Colette Felton from UC Santa Cruz.
The presentation will demonstrate how NGPS technology validates transcriptomics predictions by confirming protein presence, abundance, and modifications. Dr. Felton will discuss using long-read RNA sequencing to detect variants in cancer genes and applying NGPS for protein-level validation. Quantum-Si will be available at booth #465 during ASHG 2024.
Quantum-Si (Nasdaq: QSI) ha annunciato la sua partecipazione al 2024 American Society of Human Genetics Annual Meeting, dove presenter脿 la tecnologia Next-Generation Protein Sequencing (NGPS). La presentazione, intitolata 'Dalla Predizione alla Proteina: Validazione dei Dati Transcriptomici con la Tecnologia di Sequenziamento delle Proteine di Nuova Generazione di Quantum-Si', vedr脿 la partecipazione della Dott.ssa Meredith Carpenter e della Dott.ssa Colette Felton dell'UC Santa Cruz.
La presentazione dimostrer脿 come la tecnologia NGPS convalida le previsioni transcriptomiche confermando la presenza, l'abbondanza e le modifiche delle proteine. La Dott.ssa Felton discuter脿 dell'uso del sequenziamento RNA a lettura lunga per rilevare varianti nei geni del cancro e dell'applicazione dell'NGPS per la validazione a livello proteico. Quantum-Si sar脿 disponibile allo stand n. 465 durante l'ASHG 2024.
Quantum-Si (Nasdaq: QSI) anunci贸 su participaci贸n en la reuni贸n anual de la Sociedad Americana de Gen茅tica Humana 2024, donde presentar谩 la tecnolog铆a de Secuenciaci贸n de Prote铆nas de Nueva Generaci贸n (NGPS). La presentaci贸n, titulada 'De la Predicci贸n a la Prote铆na: Validando Datos de Transcript贸mica con la Tecnolog铆a de Secuenciaci贸n de Prote铆nas de Nueva Generaci贸n de Quantum-Si', contar谩 con la participaci贸n de la Dra. Meredith Carpenter y la Dra. Colette Felton de UC Santa Cruz.
La presentaci贸n demostrar谩 c贸mo la tecnolog铆a NGPS valida las predicciones transcript贸micas al confirmar la presencia, abundancia y modificaciones de las prote铆nas. La Dra. Felton discutir谩 el uso de la secuenciaci贸n de RNA de lectura larga para detectar variantes en genes del c谩ncer y la aplicaci贸n de NGPS para validaci贸n a nivel proteico. Quantum-Si estar谩 disponible en el stand #465 durante el ASHG 2024.
Quantum-Si (Nasdaq: QSI)電 2024雲 氙戈淡 鞚戈皠 鞙犾爠頃欗殞 鞐半 須岇潣鞐 彀胳棳頃 瓴冹澊霛缄碃 氚滍憸頃橂┌ 彀劯雽 雼氨歆 鞁滍鞁(NGPS) 旮办垹鞐 雽頃 氚滍憸頃 鞓堨爼鞛呺媹雼. '鞓堨浮鞐愳劀 雼氨歆堦箤歆: Quantum-Si鞚 彀劯雽 雼氨歆 鞁滍鞁 旮办垹搿 鞝勳偓觳 雿办澊韯半ゼ 瓴歃濏晿旮'霛茧姅 鞝滊鞚 氚滍憸鞐 UC 靸岉儉韥（歃堨潣 Meredith Carpenter 氚曥偓鞕 Colette Felton 氚曥偓臧 彀胳棳頃 瓴冹瀰雼堧嫟.
鞚 氚滍憸電 NGPS 旮办垹鞚 雼氨歆堨潣 臁挫灛, 鞏 氚 氤頇旊ゼ 頇曥澑頃溂搿滌崹 鞝勳偓觳 鞓堨浮鞚 頇曥澑頃橂姅 氚╇矔鞚 鞁滌棸頃 瓴冹瀰雼堧嫟. Felton 氚曥偓電 鞎 鞙犾爠鞛愳棎靹 氤鞚措ゼ 臧愳頃橁赴 鞙勴暅 鞛レ嫓臧 RNA 鞁滍鞁 靷毄瓿 雼氨歆 靾橃 瓴歃濎潉 鞙勴暅 NGPS 鞝侅毄鞐 雽頃 雲检潣頃 瓴冹瀰雼堧嫟. Quantum-Si電 ASHG 2024 旮瓣皠 霃欖晥 攵鞀 #465鞐愳劀 毵岆偁 靾 鞛堨姷雼堧嫟.
Quantum-Si (Nasdaq: QSI) a annonc茅 sa participation 脿 la r茅union annuelle de la Soci茅t茅 Am茅ricaine de G茅n茅tique Humaine 2024, o霉 elle pr茅sentera la technologie de S茅quen莽age des Prot茅ines de Nouvelle G茅n茅ration (NGPS). La pr茅sentation, intitul茅e 'De la Pr茅diction 脿 la Prot茅ine : Validation des Donn茅es Transcriptomiques avec la Technologie de S茅quen莽age des Prot茅ines de Nouvelle G茅n茅ration de Quantum-Si', sera anim茅e par Dr Meredith Carpenter et Dr Colette Felton de l'UC Santa Cruz.
Cette pr茅sentation d茅montrera comment la technologie NGPS valide les pr茅dictions transcriptomiques en confirmant la pr茅sence, l'abondance et les modifications des prot茅ines. Dr Felton discutera de l'utilisation du s茅quen莽age d'ARN 脿 longue lecture pour d茅tecter des variants dans les g猫nes du cancer et de l'application de NGPS pour la validation au niveau des prot茅ines. Quantum-Si sera pr茅sent au stand n掳465 lors de l'ASHG 2024.
Quantum-Si (Nasdaq: QSI) gab seine Teilnahme am j盲hrlichen Treffen der American Society of Human Genetics 2024 bekannt, wo es die Technologie Next-Generation Protein Sequencing (NGPS) pr盲sentieren wird. Die Pr盲sentation mit dem Titel 'Von der Vorhersage zum Protein: Validierung von Transkriptomdaten mit der Next-Generation Protein Sequencing Technologie von Quantum-Si' wird von Dr. Meredith Carpenter und Dr. Colette Felton von der UC Santa Cruz gehalten.
Die Pr盲sentation wird zeigen, wie die NGPS-Technologie Transkriptom-Vorhersagen validiert, indem sie die Anwesenheit, F眉lle und Modifikationen von Proteinen best盲tigt. Dr. Felton wird die Verwendung von Langlese-RNA-Sequenzierung zur Entdeckung von Varianten in Krebsgenen und die Anwendung von NGPS zur Validierung auf Proteinebene er枚rtern. Quantum-Si wird w盲hrend der ASHG 2024 am Stand #465 verf眉gbar sein.
- None.
- None.
"From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si鈥檚 Next-Generation Protein Sequencing鈩 Technology"
The presentation, titled 鈥淔rom Prediction to Protein: Validating Transcriptomics Data with Quantum-Si鈥檚 Next-Generation Protein Sequencing Technology,鈥 features insights from both Quantum-Si and a leading academic researcher on the intersection of transcriptomics and proteomics.
Quantum-Si鈥檚 Head of Scientific Affairs, Dr. Meredith Carpenter, will be joined by Dr. Colette Felton, a postdoctoral scholar from the Angela Brooks lab at the University of
"Genomic and transcriptomic data are powerful tools for understanding genetic variation and RNA expression patterns, but they often fall short in capturing the full complexity of the picture at the protein level," said Dr. Carpenter. 鈥淣GPS bridges this critical gap, directly analyzing proteoforms predicted by RNA sequencing to give researchers a reliable, high-resolution view of protein diversity and insight into functional impact.鈥
In her portion of the presentation, Dr. Felton will highlight recent advances in using long-read RNA sequencing to detect novel variants, such as single nucleotide variants (SNVs), insertions, deletions, and gene fusions, in cancer genes. She will then discuss how she is applying NGPS to validate the presence of these variants at the protein level, which is crucial for understanding their role in disease, and will review recent data demonstrating the ability of NGPS to detect proteoform-specific variation.
"Our NGPS technology empowers researchers to confirm the presence of predicted proteoforms directly at the protein level, complementing the innovative discoveries in transcriptomics," said Jeff Hawkins, CEO of Quantum-Si. "Our collaboration with UC Santa Cruz reflects our commitment to advancing multi-omics research through impactful partnerships that drive scientific progress."
To meet the team at ASHG 2024, attendees can visit booth #465.
For more information on Quantum-Si鈥檚 technology and research applications, please visit The Protein Sequencing Company鈩 | Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company鈩, is focused on revolutionizing the growing field of proteomics. The Company鈥檚 Platinum庐 instrument enables Next-Generation Protein Sequencing鈩 that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at or follow us on or .
View source version on businesswire.com:
Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What will Quantum-Si (QSI) present at ASHG 2024?
How does Quantum-Si's NGPS technology complement RNA sequencing?
Who are the key speakers at Quantum-Si's ASHG 2024 presentation?
Where can attendees find Quantum-Si at ASHG 2024?
